FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...
Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double
Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...
STAT21d
Novo Nordisk is slammed by U.K. trade group for not disclosing payments to health and patient groups
Novo Nordisk was harshly criticized by a U.K. trade ... of the company and demonstrated poor governance and a lack of care in relation to the application of the disclosure processes.” ...
Yahoo Finance11d
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?
Novo Nordisk NVO is scheduled to report fourth ... NVO operates under two segments — Diabetes and Obesity Care and Rare disease. Revenue growth in the fourth quarter of 2024 is expected to ...
AOL28d
Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations
including Novo Nordisk's (NVO) blockbuster GLP-1s. Novo traded 4% lower on the news Friday. Diabetes drug Ozempic and weight-loss drug Wegovy top the list, along with a number of others like Merck ...
NBC Washington16d
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...